{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:04:22Z","timestamp":1770498262371,"version":"3.49.0"},"reference-count":9,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Gemcitabine, a cytosine analogue, is a cytotoxic agent commonly used in the treatment of patients with a variety of solid tumours, including non-small cell lung cancer, cholangiocarcinoma and breast, pancreatic, testicular and ovarian cancers. Although generally well-tolerated, several reports suggest that it can rarely cause myositis. We present a case of gemcitabine-induced myositis in a patient with pancreatic adenocarcinoma and review the literature on this topic.<\/jats:p>","DOI":"10.1136\/bcr-2024-259660","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:45:19Z","timestamp":1737503119000},"page":"e259660","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Gemcitabine-induced myositis in a patient with pancreatic cancer"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7370-4075","authenticated-orcid":false,"given":"Zach","family":"Rubnitz","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Nevala-Plagemann","sequence":"additional","affiliation":[{"name":"Medical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5558-753X","authenticated-orcid":false,"given":"Vaia","family":"Florou","sequence":"additional","affiliation":[{"name":"Medical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[{"name":"Medical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"2025082802104086000_18.1.e259660.1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3904\/kjim.2015.176","article-title":"Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis","volume":"32","author":"Chun","year":"2017","journal-title":"Korean J Intern Med"},{"key":"2025082802104086000_18.1.e259660.2","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-199904000-00011"},{"key":"2025082802104086000_18.1.e259660.3","unstructured":"Inc., H.P.U . GEMCITABINE- gemcitabine injection, powder, lyophilized, for solution U.S. Food and Drug Administration, labels. 2021."},{"key":"2025082802104086000_18.1.e259660.4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.semarthrit.2013.11.009","article-title":"Gemcitabine-induced myopathy","volume":"43","author":"Spielmann","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2025082802104086000_18.1.e259660.5","doi-asserted-by":"crossref","DOI":"10.1177\/11795476231156290","article-title":"Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report","volume":"16","author":"Badran","year":"2023","journal-title":"Clin Med Insights Case Rep"},{"key":"2025082802104086000_18.1.e259660.6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-011-0672-8","article-title":"Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review","volume":"106","author":"Pentsova","year":"2012","journal-title":"J Neurooncol"},{"key":"2025082802104086000_18.1.e259660.7","first-page":"523","article-title":"Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel","volume":"25","author":"Ardavanis","year":"2005","journal-title":"Anticancer Res"},{"key":"2025082802104086000_18.1.e259660.8","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-11-33","article-title":"Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report","volume":"11","author":"Syrios","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"2025082802104086000_18.1.e259660.9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clon.2011.02.007","article-title":"Gemcitabine-induced acute myositis in a patient with duodenal cancer","volume":"23","author":"Wong","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-259660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:10:48Z","timestamp":1756372248000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-259660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bcr-2024-259660"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-259660","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}